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Abstract
CommerciallyavailableHIV-1drugresistance(HIVDR)genotypingassaysareexpensiveandhavelimitationsindetectingnon-B
subtypes and circulating recombinant forms that are co-circulating in resource-limited settings (RLS). This study aimed to
optimize a low cost and broadly sensitive in-house assay in detecting HIVDR mutations in the protease (PR) and reverse
transcriptase (RT) regions of pol gene. The overall plasma genotyping sensitivity was 95.8% (N=96). Compared to the original
in-house assay and two commercially available genotyping systems, TRUGENEH and ViroSeqH, the optimized in-house assay
showed a nucleotide sequence concordance of 99.3%, 99.6% and 99.1%, respectively. The optimized in-house assay was more
sensitive in detecting mixture bases than the original in-house (N=87, P,0.001) and TRUGENEH and ViroSeqH assays. When
the optimizedin-house assay wasapplied togenotypesamplescollectedforHIVDR surveys(N=230),all 72 (100%)plasmaand
69 (95.8%) of the matched dried blood spots (DBS) in the Vietnam transmitted HIVDR survey were genotyped and nucleotide
sequence concordance was 98.8%; Testing of treatment-experienced patient plasmas with viral load (VL) $ and ,3 log10
copies/ml from the Nigeria and Malawi surveys yielded 100% (N=46) and 78.6% (N=14) genotyping rates, respectively.
Furthermore, all 18 matched DBS stored at room temperature from the Nigeria survey were genotyped. Phylogenetic analysis
of the 236 sequences revealed that 43.6% were CRF01_AE, 25.9% subtype C, 13.1% CRF02_AG, 5.1% subtype G, 4.2% subtype
B, 2.5% subtype A, 2.1% each subtype F and unclassifiable, 0.4% each CRF06_CPX, CRF07_BC and CRF09_CPX.
Conclusions: The optimized in-house assay is broadly sensitive in genotyping HIV-1 group M viral strains and more sensitive
than the original in-house, TRUGENEH and ViroSeqH in detecting mixed viral populations. The broad sensitivity and
substantial reagent cost saving make this assay more accessible for RLS where HIVDR surveillance is recommended to
minimize the development and transmission of HIVDR.
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Introduction
Treatment of HIV-1 infection with highly active antiretroviral
therapy (HAART) in the past decades has remarkably reduced HIV/
AIDS related mortality and morbidity. However, the emergence of
drug resistance in persons on antiretroviral therapy (ART) and the
transmission of drug-resistant HIV strains to newly infected persons
are a major threat to the global success on HIV prevention and
treatment effort [1,2,3]. Recent years, under multilateral supports for
HIV treatment and prevention programs, especially the U.S.
President Emergency Plan for AIDS Relief (PEPFAR) with the
targets of treating two million HIV-infected people with ART,
preventing five million new HIV infection and care for 10 million
HIV-infected people and AIDS orphans, access to antiretroviral drugs
(ARVs) has been scaled up rapidly in resource-limited countries where
availability of laboratory monitoring is often limited or lacking [4,5].
This creates the potential for HIV drug resistance (HIVDR)
emergence and transmission in these settings. Detection and
monitoring of HIVDR by molecular genotyping is pivotal to ensure
ongoing regimen efficacy. It is the standard of care in resource-rich
countries [2,6]; however in resource-limited countries, HIVDR testing
is not generally available or it is too costly to be used in routine
monitoring of patients receiving ARVs. Therefore, the World Health
Organization (WHO) recommends population-based surveillance and
monitoring of HIVDR in resource-limited settings[2,4,7].Pattern and
rates of transmitted and acquired drug resistant HIV variants will
collectively inform regional and global recommendations on which
ARVs to maintain or change in first and second-line regimens [7].
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ViroSeqH, TRUGENEH and in-house assays are widely used, and
the most informative and affordable genotyping methods for
monitoring patients on ART in clinical practice [8,9,10,11].
However, ViroSeqH and TRUGENEH, the two FDA-approved
genotyping assays were designed for HIV-1 group M subtype B
viruses which are the predominant HIV-1 strains in resource-rich
countries. In addition, these commercial kits are expensive and less
sensitive to non-B subtypes, limiting their utility in resource-limited
settings [12,13,14]. There have been no commercially available
HIV-1 genotyping assays designed for non-B subtypes and
circulating recombinant forms (CRFs) that are predominant viral
strains in resource-limited countries. Moreover, the demand for
low cost and sensitive genotyping methods is increasing with the
establishment and expansion of laboratory molecular monitoring
in these settings [15,16].
The most frequently used HIVDR genotypic assays are assays
that detect resistance mutations in the reverse-transcriptase (RT)
and protease (PR) genes [17,18,19]. The minimal genotyping
requirements for these two regions are PR codons 10–99 and RT
codons 41–240 [3,20,21]. Our original in-house assay [22] has its
limitations: (1). It does not cover the entire PR gene region
required for resistance testing; (2). For some HIV-1 subtypes or
CRFs, some sequencing primers generate higher background
noises which would affect the detection of mixture bases. We
redesigned two primers for RT-PCR, one for nested PCR and four
sequencing primers in the optimized assay.
In-house assays are relatively inexpensive and sensitive for
multiple subtypes, but in-house assays should only be implemented
after adequate validation, including evaluating assay’s perfor-
mance with various HIV-1 subtypes and CRFs [3,20,23]. Factors
that could contribute to genotyping quality include type of assay/
kit used, specimen handling and storage, level of experience of
technicians performing the analysis, heterozygosity of sequences,
and viral subtypes in clinical samples [11,21]. In this study,
therefore, we validated sensitivity, accuracy and specificity of the
optimized in-house assay. We also evaluated the assay applicability
to HIVDR surveillance and monitoring.
Materials and Methods
Samples
A total of 381 samples were used in this study: 151 samples were
used for validation and 230 for application. For validation, we
included 111 HIV-1 positive plasma and 10 dried blood spot
(DBS) samples, as well as 30 HIV-1 negative DBS samples. For
application, we tested 132 plasma and 98 DBS samples. The
detailed information on these samples is described in Table 1.
Dried blood spot sample preparation and storage
Dried blood spot samples were prepared by spotting 100 mlo f
whole blood onto each of the five preprinted circles on a Whatman
903 filter paper (Whatman Inc, Piscataway, NJ) and were then
dried overnight at ambient temperature. The next day, a piece of
glassine paper was folded and a DBS card was placed in the folded
paper, and 10–20 wrapped DBS cards were then packaged in a
Bitran bag containing desiccant sacks and a humidity indicator
card and sealed. The packaged DBS cards were stored either at
270uC for Vietnam samples or at room temperature for an
average of 85.31642.66 days (median 83.5 days) for Nigeria
samples. The DBS cards were shipped to the WHO Specialized
Drug Resistance Laboratory at the Centers for Disease Control
and Prevention (CDC) (Atlanta, GA, USA) either on dry ice for
the samples from Vietnam or at ambient temperature for the DBS
samples from Nigeria. All samples were stored at 270uC upon the
arrival at CDC.
Viral RNA and total nucleic acid extraction
The QIAamp mini-viral RNA kit (Qiagen, Valencia, CA) was
used to extract RNA from all plasma samples for validation
purpose. Details for viral load (VL) measurement on samples from
Cameroon, Thailand and Zambia were described previously
Table 1. Summary of samples used in the study, including plasma and dried blood spots (DBS).
Origin
No. of
samples
Type of
sample
Collection
year
ART
status
Median
VL log10 (range)
Storage
condition VL measurement
Samples For validation (N=151)
Cameroon 38 Plasma 2007 Experienced 4.05 (2.60–5.57) 270uC Roche Amplicor v1.5
Thailand 31 Plasma 2006 Naı ¨ve 4.65 (3.14–5.58) 270uC Roche COBAS TaqMan
Zambia 27 Plasma 2006–2007 Experienced 4.26 (3.34–5.88) 270uC Roche Amplicor v1.5
30
a DBS 2005–2006 Not applicable Not applicable 270uC Not applicable
PT panels 15 Plasma 2009–2010 NA
d 4.13 (3.93–4.75) 270uCN A
10 DBS 2010 NA 3.78 (3.23–4.29) 270uC or 5 DBS
shipped at ambient
NA
Samples for application (N=230)
Vietnam 72 Plasma 2007–2008 Naı ¨ve Not done 270uC Not done
72
b DBS 2007–2008 Naı ¨ve Not done 270uC Not done
Malawi 34 Plasma 2009 Experienced 4.07 (2.25–5.89) 270uC Abbott m2000rt
Nigeria 26 Plasma 2009 Experienced 4.02 (2.18–6.41) 270uC BioMerieux EasyQ
26
c DBS 2009 Experienced 3.97 (2.18–5.64) Room temperature
for an average 85 days
BioMerieux EasyQ
aHIV negative specimens collected from pregnant women in Tanzania used for assay specificity analysis;
b Plasma-matched DBS samples collected from voluntary
counseling and testing (VCT) sites in Ho Chi Minh City enrolled in an HIV-1 threshold survey;
cPlasma-matched DBS samples collected from patients enrolled in the
Nigeria HIVDR perspective monitoring survey at 12-15 months after commencement of first line antiretroviral therapy;
d Not available.
doi:10.1371/journal.pone.0028184.t001
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preparation system (0.2 ml extraction protocol) was used to extract
the plasma RNA. For Nigeria and Vietnam plasma and DBS
samples, the NucliSensH EasyMAG
TM automatic sample prepa-
ration system (BioMe ´rieux, Durbam, NC) was used to extract the
plasma RNA and blood total nucleic acid (TNA). To extract TNA,
one DBS spot was cut out per specimen and placed in a 2ml of
NucliSENSH lysis buffer (Biomeriuex, Durham, NC) for 30 min at
room temperature with gentle rotation. Nucleic acid was then
extracted from DBS samples using the NucliSENSH EasyMagH
automated extraction system following the manufacturer’s instruc-
tions. Nucleic acid was eluted in 25 ml of NucliSENSH Extraction
Buffer 3 and stored at 280uC until use.
RT-PCR and nested PCR
Sequences of RT-PCR and sequencing primers that were re-
designed or modified based on the original assay [22] and HIV-1
sequences available at the Los Alamos HIV Database (www.hiv.
lanl.gov) are shown in Table 2. Three RT-PCR and four
sequencing primers were replaced during the optimization process.
All primers used were synthesized at CDC Biotechnology Core
Facility. Two oligonucleotides that mixed at a ratio of 1:1 (w/w)
were used as the forward primer for one step RT-PCR. One-step
RT-PCR was performed in a 50 ml reaction, which consisted of
10 ml of RNA or TNA extracts, 0.16 mM each of primers PRTM-
F1 and RT-R1, and 0.5 ml SuperScript
TM III one step RT/
PlatinumH Taq high Fidelity Enzyme Mix and 1x reaction buffer
mixture containing Mg2+ and eoxyribonucleotide triphosphates
(dNTPs) (Invitrogen, Carlsbad, CA). RT-PCR condition was an
initial cycle RT step at 50uC for 45 min and 94uC for 2 min, and
followed by 40 cycles of PCR at 94uC for 15 sec, 50uC for 20 sec,
72uC for 2 min and an extension at 72uC for 10 min. For nested
PCR, 2 ml of RT-PCR product was added to a 50 ml reaction
containing 0.12 mM of each of the inner primers PRT-F2 and RT-
R2, 1x GeneAmp Gold Buffer II, 2 mM MgCl2, 400 mM each
dNTP and 2.5 U of AmpliTaq Gold LD DNA polymerase
(Applied Biosystems, Foster City, CA). After initial denaturation at
94uC for 4 min, 40 cycles of PCR were performed in GeneAmp
9700 thermocycler with the PCR conditions as 94uC for 15 sec,
55uC for 20 sec and 72 for 2 min and following an extension at
72uC for 10 min. In the case of the failed first RT-PCR attempt,
PRTM2-F1 was used as rescue primer to replace PRTM-F1 to
account for mutations occurring within the primer binding site.
The nested PCR product was confirmed by 1% agarose gel
electrophoresis with a product size of 1,084 base pairs. The
confirmed PCR products were purified using Exo-SAP IT PCR
purification kits and used for cycle sequencing reaction with
BigDye terminator cycle sequencing kit 3.1 (Applied Biosystems,
CA).
Sequence analysis
DNA sequencing of HIV-1 pol was performed in 3730 DNA
genetic analyzer (Applied Biosystems). Six sequencing primers
overlapping the entire amplicon were used (Table 2). Sequencing
raw data were edited with ChromasPro, v1.5 (Technelysium Pty
Ltd, Australia) and confirmed by a second technician. To double
check for all mixed bases, we also used a web-based sequence
analysis tool, ReCall [26], in which minor peak calling was set at
15% of the main peak. To rule out PCR contamination,
phylogenetic analyses were performed on all newly obtained
sequences by MEGA 4 [27]. Sequence quality was also checked by
Stanford HIVdb program. Sequences with frame shifts or stop
codons were excluded from analysis. For transmitted HIVDR
surveillance, WHO surveillance drug resistance mutation (SDRM)
list was used [28]. For HIVDR monitoring surveys, drug
resistance-associated mutations in PR and RT were interpreted
using the Stanford Genotypic Resistance Interpretation Algorithm
(http://hivdb.stanford.edu/pages/algs/HIVdb.html). Pairwise nucleo
tide sequence identity and discrepancy were analyzed using BioEdit
[29].
Sensitivity, accuracy and specificity of the assay
As for HIV-1 drug resistance genotyping, there are no
standardized or reference method (gold standard) to evaluate
analytic and clinical performance in molecular genotyping for
HIV-1 group M viruses. We validated the new method according
to WHO/HIVResNet drug resistance guidelines [21], including
participation in an external quality assessment (EQA) program,
proficiency testing (PT) panels and comparing the results between
new method and the original method already established in our
laboratory [22].
Because the validation criteria were difficult to define based on
the complexity of samples tested in this multi-subtype evaluation
and all currently available assays (commercial or in-house) were
unable to genotype 100% of the samples tested [16], for this study
we used the genotyping sensitivity intervals as $95% for samples
Table 2. Primers used in the optimized in-house assay.
Primer name Sequence (59R39)
Location
(based on HXB2) Purpose
PRTM-F1* F1a-TGAARGAITGYACTGARAGRCAGGCTAAT
F1b-ACTGARAGRCAGGCTAATTTTTTAG
2057–2085
2068–2092
RT-PCR, one of mixture components
RT-PCR, one of mixture components
PRTM2-F1 TAGGGA RAATYTGGCCTTCC 2090–2109 Rescue RT-PCR primer
RT-R1 ATCCCTGCATAAATCTGACTTGC 3370–3348 RT-PCR
PRT-F2 CTTTARCTTCCCTCARATCACTCT 2243–2266 Nested PCR & sequencing
RT-R2 CTTCTGTATGTCATTGACAGTCC 3326–3304 Nested PCR & sequencing
SeqF3 AGTCCTATTGARACTGTRCCAG 2556–2577 Sequencing
SeqR3 TTTYTCTTCTGTCAATGGCCA 2639–2619 Sequencing
SeqF4 CAGTACTGGATGTGGGRGAYG 2869–2889 Sequencing
SeqR4 TACTAGGTATGGTAAATGCAGT 2952–2931 Sequencing
*: PRTM-F1 is a mixture of primers F1a and F1b at a ratio of 1:1 (w/w).
doi:10.1371/journal.pone.0028184.t002
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99% of known DR mutation codons, and reproducibility/
precision was defined as $98% nucleotide identities in $ 90%
of pairwise comparisons. In this study, sensitivity and reproduc-
ibility of the assay were assessed by comparing the current
genotyping results from 96 field collected samples of known VL
with those of the original assay [22] from Cameroon, Zambia and
Thailand. The assay was also evaluated using TRUGENEH
system GL12 with plasma from DigitalPT (N=5), a HIVDR PT
program offered by AccuTest at Boston, MA, USA and using
ViroSeqH system v 2.8 with plasma from Virology Quality
Assurance program (VQA, N=5), a WHO-sponsored HIIVDR
PT program and offered by VQA at Chicago, IL, USA.
Additionally, the precision of the assay was evaluated using 4
replicates of a second VQA plasma PT panel (N=5) and 3 of 4
replicates were tested with the optimized in-house assay and the
remaining one was tested with TRUGENEH. The precision test
was performed by 3 technicians. In addition, 10 DBS panels
shipped at two different temperature conditions from VQA were
also tested by the optimized assay. Specificity was determined by
testing 30 HIV-negative DBS specimens collected from pregnant
women in Tanzania.
Applying the assay for surveillance of transmitted HIVDR
and HIVDR prevention monitoring surveys in resource-
limited countries
Seventy two matched plasma and DBS samples from newly HIV-
diagnosed persons in Vietnam were tested. For HIVDR monitoring
surveys, we applied the optimized assay for resistance testing in
samples collected from patients 12–15 months after the commence-
mentof ARTintwomonitoring surveys. Forthe Malawimonitoring
survey, 34 plasma samples from patients with VL ranged from 2.25
to 5.89 log10 copies/ml were tested. In Nigeria monitoring survey,
26 matched plasma and DBS samples with plasma VL ranged from
2.18 to 6.41 log10 copies/ml were analyzed.
HIV-1 subtyping
HIV-1 subtyping for the newly obtained sequences was
performed using the REGA 4 HIV-1 Genotyping Tool [30].
Phylogenetic analyses were further conducted using neighbor-
joining method included in the MEGA 4 for sequences with
unclassifiable subtypes. Reference sequences were obtained from
the Los Alamos HIV Database (www.hiv.lanl.gov). Sequences
obtained in the study were submitted to GenBank and their
accession numbers are JN885633 to JN885719.
Reagent cost comparison
To estimate reagent cost savings by using the optimized broad
sensitive genotyping assay, we calculated reagent cost per test of
the assay and compared it with the reagent costs of commercially
available genotyping systems, TRUGENEH and ViroSeqH.W e
used current U.S. market values in dollars for all the reagents we
used in the in-house assay including RNA/TNA extraction, RT-
PCR, nested PCR, PCR amplification confirmation, PCR
purification and sequencing reactions. These reagent cost
estimates did not include the cost for running test controls and
any repetitions when needed.
Statistical analysis
Wilcoxon Signed-Rank test was used to analyze the difference
in number of nucleotide mixtures detected between the optimized
and original in-house assays. The statistical significance was
considered when P value was ,0.05.
Ethical consideration
In accordance with United States regulations and international
guidelines, the CDC human subjects review process determined
this activity to be non-research and the protocol was approved by
the Associate Director for Science (ADS), National Center for
HIV, Hepatitis, STD and TB Prevention, CDC, Atlanta. All the
study protocols were approved by local institutional review boards:
the National Health Sciences Research Committee, Ministry of
Health of Malawi; the National Institute for Medical Research at
Lagos, Nigeria; the Thailand Ministry of Public Health and
Sirriraj Hospital, Mahidol University, Thailand; the University of
Alabama, Birmingham and the University of Zambia Research
Ethics Committee, Zambia.
Results
Validation of the optimized in-house assay
Sensitivity. The sensitivity of the optimized in-house assay
was evaluated with 96 HIV-1 positive plasma samples collected
from Cameroon, Thailand and Zambia. Of these, all 5 samples
with VL ,3 log10 copies/ml and 87 (95.6%) of 91 samples with
VL $3 log10 copies/ml were genotyped, resulting in an overall
genotyping rate of 95.8% (92/96) comparing to 96.8% (93/96) by
the original assay.
Accuracy. The accuracy of the optimized assay was first
assessed by comparing 87 paired nucleotide sequences generated
by the original in-house assay [22] and the optimized assay using
ReCall and BioEdit programs. The mean nucleotide identity was
99.360.50% (mean 6 SD) among paired nucleotide sequences.
Wilcoxon signed-rank test was used to compare original and
optimized in-house assays in basecalling for mixed bases and
revealed that the optimized assay detected significantly more
mixed bases than the original one (P,0.001). However, this
difference did not translate into differences in HIVDR mutations.
Among 144 DR mutations detected in paired samples, we did not
detect any complete discordant mutations at DR mutation sites
and only 11 partially discordant DR mutation sites including 3 in
PR and 8 in RT (Table 3) were seen. The overall DR codon
agreement was 99.8% between the 87 paired samples.
Testing 10 plasma PT panel samples (five from DigitalPT and
five from VQA) using the optimized in-house and TRUGENEH or
ViroSeqH assays also indicated that the optimized in-house assay
appeared to detect more mixed bases than commercial kits.
However, DR mutation site differences only occurred in 2 of 76
DR mutations between the optimized in-house and TRUGENEH
and 2 of 44 between the in-house and ViroSeqH in mixed bases.
The overall sequence identity was 99.660.41% between the in-
house and TRUGENEH (Table 4), and 99.160.65% between the
in-house and ViroSeqH (Table 5). Further examination to see
whether more sensitive detection of base mixtures in the optimized
in-house assay is a reproducible event, we analyzed 4 replicates of
5 samples that were tested by three optimized in-house assay runs
and one TRUGENEH run under different operators. We found
highly concordant sequence identities ranging from 98.22% to
99.65%. The minor differences observed in sequence identity were
caused by base mixtures (Table 6). For example, at codons 37 and
41 of RT in sample 3 (Fig 1), one replicate detected mixture RY at
the 2
nd and 3
rd positions of codon 37, and the second replicate did
not find any mixtures, while the third replicate showed lower, yet
visible, second peaks comparing to the first replicate. Similarly at
the 2
nd position of codon 41, the first replicate revealed a Y (C/T),
the second replicate showed a W (A/T), and the third replicate
revealed an H (A/C/T) while TRUGENEH replicate detected a Y
(C/T). Nucleotide mixtures also caused some mismatched DR
A Low Cost and Sensitive HIV-1 Genotyping Assay
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replicate missed 3 mixed codons (K65KR, D67DN and T69IT) in
sample 2 among the 4 replicates. However, the minor peaks of
nucleotide bases at these three codons could be seen, but were
below the mixture cutoff (15%) on the chromatogram by ReCall.
Thus these mixtures were not counted and resulted in the codon
discrepancy. Another partial discordant example was the DR
mutation M184MV, which was detected in sample 5 by all 3 in-
house replicates but not found in TRUGENEH replicate. These
results indicated that the sequences generated by population-based
sequencing were highly reproducible but the sensitivity at
detecting low frequency of drug resistant HIV variants was very
challenging.
Table 3. Discordant drug resistance-associated amino acid positions in protease and reverse transcriptase from 87 plasma
samples
a genotyped by the original and optimized in-house assays.
Amino acid
position Mutation
Amino acid detected in
the original assay
(No. of sample)
Amino acid detected in
the newly optimized assay
No. partially
discordant
mutation
Protease
32
V32A V (87) V (86), AV (1) 1
33 L33F L (84), F (3) L (84), F (3) 0
35 E35G G (86), EG (1) G (85), EG (2) 1
71 A71V A (86), V (1) A (86), AV (1) 1
74 T74S T (82), S (5) T (82), S (5) 0
Reverse Transcriptase
62
A62V A (86), AV (1) A (86), AV (1) 0
65 K65R K (86), R (1) K (86), KR (1) 1
67 D67N D (86), DN (1) D (86), DN (1) 0
69 T69S/N T (82), ST (1), N (1), NT (3) T (82), ST (1), N (1), NT (3) 0
90 V90I V (85), I (1), IV (1) V (85), IV (2) 1
98 A98G A (86), G (1) A (86), G (1) 0
101 K101E/Q K (84), E (2), Q (1) K (84), E (2), Q (1) 0
103 K103N K (77), N (8), KN (2) K (76), N (8), KN (3) 1
106 V106A/I V (82), A (1), I (3), IV (1) V (83), A (1), I (3) 1
118 V118I V (83), I (3), IV (1) V (83), I (3), IV (1) 0
138 E138A E (86), A (1) E (86), A (1) 0
179 V179D/T V (82), D (3), DV (1), T (1) V (82), D (3), DV (1), T (1) 0
181 Y181C Y (81), C (3), CY (3), Y(81), C (3), CY (3) 0
184 M184V M (78), V (8), IMV (1) M (78), V (8), IMV (1) 0
188 Y188C/L Y (85), L (1), CY (1) Y (86), L (1) 1
190 G190A G (84), A (3) G (83), A (2), AG (2) 1
210 L210F L (86), F (1) L (86), F (1) 0
215 T215A T (86), AT (1) T (87) 1
221 H221Y H (87) H (86), HY (1) 1
a: Five samples that did not generate full-length sequences for protease (codon 13 to 99) and reverse transcriptase (codon 1 to 251) were excluded for the analysis.
Among them, 4 sequences were generated by the original assay and 1 by the optimized assay.
doi:10.1371/journal.pone.0028184.t003
Table 4. Pairwise sequence identity analysis between the
optimized in-house and TRUGENEH assays.
DigitalPT panel Optimized in-house vs TRUGENE
No. of sample 5
% Nucleotide identity 99.660.40
Mean nucleotide mixture 11.4 vs 6.2
% amino acid identity 98.960.48
No. of DR mutation 76 vs 74
Partial discordant mutation (%) 2 (2.6)
doi:10.1371/journal.pone.0028184.t004
Table 5. Pairwise sequence identity analysis between the
optimized in-house and ViroSeqH assays.
VQA PT panel Optimized in-house vs ViroSeqH
No. of sample 5
% Nucleotide identity 99.160.65
Mean nucleotide mixture 26.4 vs 18.8
% amino acid identity 97.561.75
No. of DR mutation 44 vs 42
Partial discordant mutation (%) 2 (4.5)
doi:10.1371/journal.pone.0028184.t005
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mended by WHO for HIVDR surveillance in resource-limited
settings in treatment-naı ¨ve populations [21]. The mission of our
laboratory at CDC is to support HIVDR surveillance in PEPFAR-
supported countries; thus, we evaluated the assay sensitivity with
two matched DBS experimental panels shipped under different
temperature conditions from VQA. The optimized in-house assay
was able to genotype all 5 DBS samples shipped with dry ice and 4
of 5 DBS samples shipped at ambient temperature with DBS VL
ranging from 3.17 to 3.98 log10 copies/ml. The failed sample
GEN001BS.04C was the sample with the lowest VL of 3.17 log10
copies/ml (f 7).
To evaluate the specificity of the optimized in-house assay, we
tested HIV negative DBS samples (N=30) collected from women
attending ANC clinics in Tanzania and they were all found to be
negative, resulting in the assay specificity of 100%.
EQA assessment results: Based on WHO/HIVResNet require-
ment to pass the PT panels, a drug resistance mutation (DRM) site
score and nucleotide (nt) alignment score with consensus sequence
of at least 99% (considering all 5 samples) must be achieved. The
optimized in-house assay passed two sets of plasma PT panels with
100% DRM, 99.98% nt and 100% DRM, 99.88% nt scores,
respectively. The assay showed high sequence concordance with
the laboratories participating in the EQA program.
Application of the assay in the surveillance of HIVDR in
resource-poor countries
With the satisfactory validation results of the optimized in-house
assay, we applied this assay in the surveillance of HIVDR in three
PEPFAR-supported countries.
Threshold survey of transmitted HIVDR in recently HIV-
infected population in Vietnam. For this survey, we tested 72
plasma and matched DBS specimens collected from individuals
attending voluntary counseling and testing (VCT) in Ho Chi Minh
City. We were able to genotype all 72 plasma and 69 (95.8%) DBS
samples and sequence identity analysis (N=69) indicated that
overall nucleotide identity was 98.9%60.62% between matched
plasma and DBS samples. The sequence differences were caused
by partially discordant mixture bases located in the three HIVDR
codons in the RT region.
Detection of HIVDR development in ART-experienced
patients from Malawi and Nigeria. We next utilized the
optimized in-house assay in detecting HIVDR development in
patients treated with first-line ARVs for 12-15 months in two
monitoring surveys conducted in Malawi (N=34) and Nigeria
(N=26). Genotyping was successful for all 46 plasma samples
collected from virologically failed patients defined as VL $3 log10
copies/ml according to the WHO definition [4]. For patients with
VL between 2.18 and ,3 log10 copies/ml, 78.6% (11/14) plasma
samples (7/8 from Nigeria and 4/6 from Malawi) were also
successful. Furthermore, all 18 matched DBS samples from
virologically failing patients and 4 of the 8 DBS samples with
VL between 2.18 and ,3 log10 copies/ml from Nigeria were
genotyped. The nucleotide sequence identity between the 22
plasma and DBS pairs was 98.860.80%. For DR mutations,
90.4% DR mutations identified in plasma were also found in DBS.
For the 9.6% discordant DR mutations identified, majority of
them was partially discordant (7.5%) and only 2.1% were
completely discordant.
HIV -1 subtypes
Phylogenetic analyses revealed that the overall subtype
distributions among the 236 newly obtained sequences were
43.6% CRF 01_AE, 25.6% C, 13.1% CRF02_AG, 5.1% G, 4.2%
B, 2.5% A, 2.1% F, 2.1% unclassified (UC), and 0.4% each
CRF06_CPX, CRF09_CPX and CRF-07_BC. Subtype distribu-
tions are different from country to country. For instance, all
samples tested from Vietnam and Malawi were CRF-01_AE and
subtype C, respectively, while multiple subtypes were identified
from samples collected from Cameroon, Canada and Nigeria
(Table 8).
Reagent cost comparison
Using the current U.S. market values in dollars for all the
reagents used in the optimized in-house assay, we estimated that
the reagent cost per test for the optimized in-house assay was
$40.00, comparing to $213.20 for TRUGENEH and $172.86 for
ViroSeqH. In the reagent cost calculations, we did not include the
cost for assay controls and any need for repetition of tests, which
would increase the cost of reagents for all the assays compared
here.
Discussion
The newly optimized in-house assay was broadly sensitive in
genotyping multiple HIV-1 group M subtypes and CRFs from
plasma and DBS collected from 6 resource-limited countries. The
original in-house assay, although a success from the broad
sensitivity perspective, was in need for improvement due to the
concern of incomplete genotyping of PR gene and suboptimal
Table 6. Genotyping reproducibility of replicate PCR products generated from independent RT-PCR amplification process by 3
different operators in a 5-member proficiency testing panel received from VQA.
No. of drug resistance mutations
Sample ID HIV-1 VL (log10) HIV-1 Subtype
% Nucleotide
sequence identity Replicate Tests
No. Partially
discordant mutation
IH1* IH2 IH3 TG
#
1 3.76 B 98.8360.18 1 1 1 1 0
2 4.13 C 99.6560.23 10 10 7 10 3
3 4.19 F 98.2260.30 0 0 0 0 0
4 3.93 B 99.0860.11 5 5 5 5 0
5 4.75 C 99.5860.08 6 6 5 4 3
*IH1-3: tests were independently performed by 3 operators using the optimized in-house assay;
#:TRUGENEH assay.
doi:10.1371/journal.pone.0028184.t006
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re-designed RT-PCR and some of the sequencing primers in the
current study confirmed that the newly optimized in-house assay is
comparable to the original in-house assay in assay sensitivity and
specificity and it is also broadly sensitive to all group M subtypes
and CRFs circulating in PEPFAR-supported countries. Pairwise
nucleotide sequence identity analyses from sequences generated by
the optimized in-house assay and the ones obtained from the
Figure 1. Difference of mixture chromatographs generated independently by 3 different operators using the optimized in-house
assay from one PT sample. Panel A shows 2 codons (37 and 41 of RT) with nucleotide base calling of AYR; Panel B shows the AWR at codon 41
(the second peaks at codon 37 were not detected in this replicate); Panel C shows ACR at codon 37 (minor T was not called by the ReCall at the cutoff
of 15%) and AHR at codon 41 (almost equal height of second and third peak at the 2
nd position).
doi:10.1371/journal.pone.0028184.g001
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systems indicated the optimized in-house assay produced compa-
rable genotyping results. More importantly, the optimized in-
house assay expanded genotyping codon coverage to include all
PR mutations and improved sequence quality by reducing
background noises to minimal, resulting in more sensitive mixture
calling. The ability to detect nucleotide mixtures (low frequency
viral strains) is important as recent studies have demonstrated that
low frequency variants can grow rapidly and become predominant
viral population under the selective drug pressure and lead to
treatment failure [31,32].
Given that the newly optimized in-house assay was broadly
sensitive in genotyping B and non-B subtype viral strains of HIV-1
group M viruses, it would be expected that the assay would
efficiently genotype plasma and DBS samples from various
geographical areas, and this was verified by applying the assay
in genotyping samples collected from patients enrolled in two
perspective HIVDR monitoring surveys. The optimized in-house
assay was able to genotype 100% of plasma samples collected from
virological failure patients, defined as VL $3 log10 copies/ml [4]
in the present study and over three-fourths of the patients with VL
between 2.18 and ,3 log 10 copies/ml. More importantly,
genotyping was successful for all the 18 matched DBS samples
collected from Nigerian patients with virological failure. It is
worthy to note that these DBS samples had been stored at room
temperature for an average of 85 days before shipping to our
laboratory for testing. In addition, testing of two DBS PT panels
shipped frozen or at ambient temperature revealed that genotyp-
ing was successful for all DBS samples except one with the lowest
VL and shipped at ambient temperature. These results indicate
that the optimized in-house assay is highly sensitive in genotyping
both plasma and DBS samples. It is important to point out that
interpretation of the genotyping results from the DBS samples
stored at room temperature for a long period of time however,
needs to be cautious since these DBS cards were packaged
correctly and stored in an air-conditioning room with low
Table 7. Genotyping efficiency and drug resistance-associated mutations identified in protease (PR) and reverse transcriptase (RT)
by the optimized in-house assay from dried blood spots (DBS) PT panels.
Panel sample ID
Shipping
conditions
Plasma VL
(Log10)
DBS VL
(Log10)
RT-PCR
result Subtype Drug resistance mutation PR RT
DBS panel A
GEN001BS.01A Dry ice 3.78 3.51 + F None None
GEN001BS.02A Dry ice 3.73 3.76 + B None M184MV, K103N
GEN001BS.03A Dry ice 4.29 3.98 + C None M41L, K103N, M184V, T215Y
GEN001BS.04A Dry ice 3.23 3.17 + B L10I, L23I, L33F,
M46L, I54V, A71T,
V82A, N88G, L90M
M41L, E44D, A62V, D67N,
L74V, L100I, K103N, L210W,
T215Y, H221Y
GEN001BS.05A Dry ice 3.87 3.80 + B None K103N, Y181C, P225H
DBS panel C
GEN001BS.01C Ambient 3.78 3.51 + F None None
GEN001BS.02C Ambient 3.73 3.76 + B None M184MV, K103N
GEN001BS.03C Ambient 4.29 3.98 + C None M41L, K103N, Y181CY,
M184MV, T215Y
GEN001BS.04C Ambient 3.23 3.17 N/A* N/A N/A
GEN001BS.05C Ambient 3.87 3.80 + B None K103N, Y181CY, P225H
*N/A:not available; bold and underlined residues were partially discordant resistance mutations from paired DBS shipped under different temperature conditions.
doi:10.1371/journal.pone.0028184.t007
Table 8. HIV-1 subtypes and circulating recombinant forms (CRFs) from samples genotyped by the optimized in-house assay.
Sample
source
No. of
Sample A B C F G CRF01_AE CRF02_AG CRF06_CPX CRF07_BC CRF09_CPX UC
Cameroon 31 3 2 2 21 1 2
Malawi 32 32
Nigeria 25 1 10 10 1 3
Zambia 25 1 24
Thailand 31 31
Vietnam 72 72
Canada and US 20 1 10 5 3 1
Total 236 6 10 61 5 12 103 31 1 1 1 5
% subtype 100 2.54 4.24 25.85 2.12 5.09 43.64 13.14 0.42 0.42 0.42 2.12
doi:10.1371/journal.pone.0028184.t008
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the true impact of suboptimal storage conditions existed in
resource-limited settings on the quality of DBS cards and resulted
in better genotyping efficiency. Studies have shown that correct
packaging and storage of DBS are critical elements in ensuring
successful genotyping results [33,34,35,36]. In fact, our own data
here generated from two identical DBS PT panels and shipped at
frozen or ambient temperature also indicate that even overnight
exposure of DBS samples with low VL to ambient temperature in
domestic shipment could have some detrimental impact on DBS
quality for genotyping. Comparing the performance of the
optimized in-house assay with TRUGENEH, ViroSeqH and the
original in-house assay, high nucleotide sequence identity was
revealed; however, minor differences existed in mixture base
callings. The optimized in-house assay detected more mixed bases
than the commercial kits and our original in-house assay. Many
factors could contribute to the sequence discordances at the mixed
nucleotide sites in HIV genotyping including viral quasispecies,
primer binding preference and location, Taq polymerase mis-
incorporation, sequence quality, basecalling criteria or technical
errors [11,37,38]. Because HIV-1 viruses are rapidly evolving
quasispecies [39], there are multiple HIV-1 variants in one patient
[37,40]. Sequence identity and codon concordance are challeng-
ing when mixed bases are present [41]. It has been reported that
ViroSeqH detected more mixtures (78%) than an in-house assay
(22%) [10]. In contrast, our optimized in-house assay detected
more mixture bases than other assays. This may be due to the fact
that the optimized assay produced sequence chromatographs
containing minimal background noise. To confirm this, we
performed sequence editing for all validation samples (N=102)
including PT panels with ReCall program [26] using minor peak
default mixture calling setting at .15% of the major peak in bi-
directional sequences. We also independently tested one set of the
PT panels by 3 different operators. These analyses showed that the
optimized in-house assay gave more sensitive mixture calling. The
variability in detecting nucleotide mixtures was likely due to the
first-round RT-PCR [42] in sampling of quasispecies strains rather
than by technical errors in the sequencing process [43]. The use of
wide-spectrum degenerate primers and a mixture of two forward
primers at slightly different binding sites in the initial run of RT-
PCR are likely contributed to more mixtures calling in the
optimized in-house assay. To what extent and by what factors the
mixture variants could be affected and detected in HIV
genotyping is a matter of speculation, which needs further studies.
Phylogenetic analyses indicated that the optimized in-house
assay could genotype HIV-1 group M subtypes A (A1, A2), B, C, F
(F1, F2), G and CRFs including CRF01_AE, CRF02_AG,
CRF06_CPX, CRF07_BC, CRF09_CPX and UC with an overall
sensitivity of 96% using specimens from different geographical
regions around the world. Due to the limited availability of HIV-
positive samples, we only genotyped a small number of subtype A
and F viral strains and further studies are needed to confirm our
findings with larger sample sizes on these viral strains. It has been
reported that genotyping sensitivity with two FDA-approved
systems using non-B subtypes varies [44]. Some studies indicated
that these two systems performed well for B and non-B subtypes
[9,45,46,47] while others demonstrated that they were less
sensitive to non-B subtypes and CRFs [12,13,14,48]. For instance,
only 52% of serum samples were genotyped in an Ethiopian
threshold survey using ViroSeqH and TRUGENEH methods
sequentially [49]. For genotyping DBS samples collected from
subtype B infected persons, one study reported 78.8% genotyping
rate by TRUGENEH [50] while another study reported 57.5%
genotyping rate using ViroSeqH for DBS samples stored for one
year at 4uC [51]. An additional study reported an even lower DBS
genotyping rate of 38.6% by ViroSeqH system [40]. However, a
study using ViroSeqH documented 100% genotyping rate for DBS
samples collected from subtype B-infected patients with VL great
than 2,000 copies/ml and 54.5% genotyping rate with DBS
samples from patients with VL less than 2,000 copies/ml when
DBS samples were stored at optimal conditions [52]. Thus,
commercial genotyping systems might work well with DBS
samples collected from subtype-B-infected patients. Genotyping
of DBS samples using these genotyping systems in non-B subtypes
needs to be further studied. In comparison to our original in-house
assay, our own experience using these two commercial assays with
non-B subtypes was also not satisfactory. They often required
repetition of RT-PCR or sequencing due to failure to amplify or
sequence in TRUGENEH and ViroSeqH assays [12,14]. Com-
pared to these commercial assays, the optimized in-house assay
was not only sensitive, but also inexpensive. The assay could
reduce the cost for genotyping reagents by 75%. The availability
of low cost and broadly sensitive genotyping assay for plasma and
DBS would make HIVDR surveillance and monitoring in
resource-limited settings more accessible.
In conclusion, we have validated and improved a broadly
sensitive and less expensive in-house genotyping assay for HIVDR
surveillance and monitoring in resource-limited countries. Vali-
dation analyses indicate that the optimized in-house assay detected
more mixed HIV-1 population than our original in-house assay
and commercial genotyping kits. Given the high efficiency in
genotyping diverse HIV-1 group M viral strains from plasma and
DBS samples and substantial reagent cost saving, the optimized in-
house assay could be applicable to DR genotyping in both ART-
naive and -experienced populations according to current WHO
recommendations for surveillance purpose [4].
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